Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India

Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patient access. These new prices, effective April 1, aim to make the GLP-1 therapies more affordable for individuals managing diabetes and obesity. This move comes as Indian companies launch generic semaglutide following patent expiry, intensifying market competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6dhBEot
via IFTTT

Read More

Lupin gets tentative nod from USFDA for generic Sugammadex injection

Lupin Ltd, a prominent name in the pharmaceutical world, revealed on Tuesday that it has gained tentative approval from the US health authorities for its generic Sugammadex injection. This innovative solution serves to reverse the impacts of muscle relaxants administered during surgeries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SNlPyBz
via IFTTT

Read More

Novo Nordisk plans to cut price of Ozempic as generics hit market

Novo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmakers launched cheaper generic versions of semaglutide. Industry sources suggest Novo's revised price will be competitive. This strategy aims to capture a larger market share against aggressive pricing from Indian companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raAu7Yq
via IFTTT

Read More

Centre looks to trigger 'Essentials' Act to regulate prices of bulk drugs

The department of pharmaceuticals (DoP) has been holding meetings with the industry executives to take stock of the situation, people in the know said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Vf3cmQN
via IFTTT

Read More

Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution Process

The Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP) over a payment default, and appointed Rajesh Jhunjhunwala as interim resolution professional.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JNAOf7X
via IFTTT

Read More

Regulator steps up oversight of GLP-1 drug distribution chain

India's drug regulatory body is intensifying its scrutiny of the distribution channels for GLP-1 weight loss drugs. State drug authorities are directed to ensure stringent compliance with approved protocols and accurate product labeling. Any instances of unauthorized sale or marketing will invite strict legal action. The agency is also keeping a close watch on promotional activities across different platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DuZS9q6
via IFTTT

Read More

Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management drug. Biocon aims to become a global medicines company driven by innovation. Insulin remains a strategic anchor. Oncology and immunology are key pillars. New areas like ophthalmology are being explored. Investments will target technology and AI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rUT1ZgG
via IFTTT

Read More